Alongside, Novo Nordisk agreed to take over Catalents fill-finish plants in Italy, Belgium, and Indiana for $11B ( [10] )
Additionally, much of the research has focused on individuals with metabolic comorbidities, which leaves unanswered questions about the effectiveness of GLP-1 RAs in different populations
David: Brenham convinces the board that rather than merging, they should use their capital reserves to rebuild up Nordisk's own production capacity, go hire a global sales force
Medical and research articles may have details that could be upsetting to read
Its possible that Ozempic could be beneficial for your reproductive health, but this benefit is primarily associated with weight loss, rather than the medication itself